VIMTA is a one-stop solution for comparative and equivalence studies for pharmaceutical, biotechnology, and nutraceutical products. In addition to pharmacokinetic (PK), pharmacodynamic (PD), and in vitro bioequivalence (BE) testing, we also offer reliable patient-based clinical endpoint and pharmacokinetic studies.
As all drugs carry inherent safety risks, their clinical value depends on ensuring that the therapeutic benefits outweigh the associated risks. Clinical endpoint studies evaluate the therapeutic effect of a drug in the target patient population according to a predefined protocol and study objectives. The primary endpoint typically measures outcomes that are meaningful to patients, such as how they feel, function, or survive following treatment, and these studies often form the basis for regulatory approval of new drugs.
